11,256 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Two Sigma Securities LLC

Two Sigma Securities LLC bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,256 shares of the biotechnology company’s stock, valued at approximately $917,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARWR. Carolina Wealth Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the period. First Horizon Corp raised its holdings in Arrowhead Pharmaceuticals by 36.2% in the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 174 shares during the period. PNC Financial Services Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 1.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock worth $737,000 after acquiring an additional 178 shares during the period. Optiver Holding B.V. lifted its position in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Down 3.0%

NASDAQ ARWR opened at $82.39 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $21.61 and a twelve month high of $95.49. The stock has a market cap of $11.61 billion, a PE ratio of -36.62 and a beta of 1.27. The firm has a 50-day simple moving average of $83.65 and a 200 day simple moving average of $73.76. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same period last year, the company earned ($1.26) EPS. The company’s revenue was up 171.0% on a year-over-year basis. On average, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. Piper Sandler restated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target on the stock. Finally, B. Riley Financial upped their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.42.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.